humanitarian
Archived signal Translated · Español · 2–5m lag
Medicamentos para el hombre Informe Público Europeo de Evaluación (EPAR): Steqeyma, ustekinumab, Fecha de autorización: 22/08/2024, Revisión: 10, Estado: Autorizado
Medicamentos para el hombre Informe público europeo de evaluación (EPAR): Zumrad, sasaclimab, Estado: retirada de la solicitud
Reported by EMA What Is New
Read the complete report at EMA What Is New ↗
Verification notice
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
12 reports · 2 sources
EMA What Is NewMedicamentos para el hombre Informe Público Europeo de Evaluación (EPAR): Steqeyma, ustekinumab, Fecha de autorización: 22/08/2024, Revisión: 10, Estado: AutorizadoEMA What Is NewMedicamentos para el hombre Informe Público Europeo de Evaluación (EPAR): Steqeyma, ustekinumab, Fecha de autorización: 22/08/2024, Revisión: 10, Estado: AutorizadoEMA What Is NewHuman medicines European public assessment report (EPAR): Avtozma, tocilizumab, Date of authorisation: 14/02/2025, Revision: 8, Status: AuthorisedEMA What Is NewHuman medicines European public assessment report (EPAR): Avtozma, tocilizumab, Date of authorisation: 14/02/2025, Revision: 8, Status: AuthorisedEMA What Is NewMedicamentos para el hombre Informe Público Europeo de Evaluación (EPAR): Sepalna, senaparib, Estado: OpiniónEMA What Is NewHuman medicines European public assessment report (EPAR): Ruxolitinib Zentiva, ruxolitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Povofortay, povorcitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Zeydovio, glepaglutide, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Adcomfo, omalizumab, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Lifyorli, relacorilant, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Inijaq, tofacitinib, Status: OpinionEMA What Is NewHuman medicines European public assessment report (EPAR): Frehemgo, denecimig, Status: Opinion8 recorded states
Signal first indexedP2 · 99% quality · 2 sources
Headline updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources
Source details updatedP2 · 99% quality · 2 sources